Royalty Pharma
RPRX
RPRX
362 hedge funds and large institutions have $10B invested in Royalty Pharma in 2023 Q4 according to their latest regulatory filings, with 79 funds opening new positions, 146 increasing their positions, 110 reducing their positions, and 29 closing their positions.
Holders
362
Holders Change
+50
Holders Change %
+16.03%
% of All Funds
5.31%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.12%
New
79
Increased
146
Reduced
110
Closed
29
Calls
$25.5M
Puts
$17.5M
Net Calls
+$8.06M
Net Calls Change
-$20.6M
Top Buyers
| 1 |
1
Morgan Stanley
New York
|
$2.6B |
| 2 |
UE
2
Unisphere Establishment
Vaduz,
Liechtenstein
|
$140M |
| 3 |
3
Man Group
London,
United Kingdom
|
$72.4M |
| 4 |
4
Amundi
Paris,
France
|
$105M |
| 5 |
5
Swedbank
Stockholm,
Sweden
|
$154M |
